- Molecular NameFurosemide
- SynonymDihydroflumethiazide; Frusemid; Frusemide; Furosemid; Furosemida [INN-Spanish]; Furosemidu [Polish]; Furosemidum [INN-Latin]; Fursemid; Fursemida; Fursemide; Metflorylthiazidine; Methforylthiazidine
- Weight330.748
- Drugbank_IDDB00695
- ACS_NO54-31-9
- Show 2D model
- LogP (experiment)2.03
- LogP (predicted, AB/LogP v2.0)2.59
- pka3.9
- LogD (pH=7, predicted)-1.34
- Solubility (experiment)0.0724 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.13
- LogSw (predicted, AB/LogsW2.0)0.19
- Sw (mg/ml) (predicted, ACD/Labs)0.12
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds5
- TPSA131.01
- StatusFDA approved
- AdministrationOral, IV, IM
- PharmacologyA loop diuretic used in the treatment of congestive heart failure and edema.
- Absorption_value61.0
- Absorption (description)Rapidly but incompletely absorbed after oral administration.
- Caco_2-6.5
- Bioavailability60.0
- Protein binding98.6
- Volume of distribution (VD)0.13 L/kg, increased in subjects with liver disease, nephrotic syndrome, and in neonates.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic and renal glucuronidation
- Half life1.3 h, increased in subjects with renal failure, congestive heart failure, liver disease, and in neonates (up to about 46 h).
- ExcretionUp to 90% of an IV dose is excreted in the urine, mainly as unchanged drug with up to 14% of the dose as a glucuronide conjugate. 2-Amino-4-chloro-5-sulfamoylanthranilic acid has been reported as a metabolite in several studies, but in other cases it has not been detected and it has been suggested that it is an analytical artefact produced during acid extraction procedures. In normal subjects, about 6 to 18% of a dose is eliminated in the faeces after IV administration; this may be increased to about 60% in renal failure. It crosses the placenta and is found in breast milk.
- Urinary Excretion71
- Clerance1.66 ml/min/kg
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A